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Abstract
Purpose/results/discussion. Recurrent chromosomal translocations are common features of many human malignancies.
While such translocations often serve as diagnostic markers, molecular analysis of these breakpoint regions and the
characterization of the affected genes is leading to a greater understanding of the causal role such translocations play in
malignant transformation. A common theme that is emerging from the study of tumor-associated translocations is the
generation of chimeric genes that, when expressed, frequently retain many of the functional properties of the wild-type
genes from which they originated. Sarcomas, in particular, harbor chimeric genes that are often derived from transcription
factors, suggesting that the resulting chimeric transcription factors contribute to tumorigenesis. The tumor-speci® c
expression of the fusion proteins make them likely candidates for tumor-associated antigens (TAA) and are thus of interest
in the development of new therapies. The focus of this review will be on the translocation events associated with Ewing’s
sarcomas/PNETs (ES), alveolar rhabdomyosarcoma (ARMS), malignant melanoma of soft parts (MMSP) (clear cell
sarcoma), desmoplastic small round cell tumor (DSRCT), synovial sarcoma (SS), and liposarcoma (LS), and the potential
for targeting the resulting chimeric proteins in novel immunotherapies.
Introduction
Chromosomal abnormalities are common in human
tumors with many malignancies exhibiting clonal
chromosomal aberrations.
1 The identi® cation of tu-
mor-speci® c chromosomal translocations aids in di-
agnosis and serves as a prognostic indicator.
2± 6 With
an increasing understanding of the effect these
events have on normal cellular processes, novel ther-
apies can be developed which have greater
speci® city and ef® cacy.
Two major consequences of chromosomal rear-
rangements in tumors have been identi® ed: the acti-
vation of an oncogene, or the creation of a novel
oncogenic protein. First, translocations can result in
the activation of genes located at or near the break-
point. Often, these genes normally function in the
promotion of cell growth and differentiation. Thus,
their disruption can affect normal cell regulation.
This type of alteration, which is most common in
hematological malignancies, is illustrated by the
t(8;14) translocation associated with Burkitt’s
lymphoma in which c-MYC is activated by reposi-
tioning under the control of the potent Ig enhancer.
1
An alternative consequence of chromosomal
translocations is the generation of functional
chimeric genes. This scenario is most common in
solid tumors and usually involves unrelated genes.
Often, these translocation events affect genes encod-
ing transcription factors, thereby generating
chimeric transcription factors with properties of
both genes (Table 1). The fusion proteins often
exhibit the DNA-binding speci® city of one gene
with the activation domain of the other gene. Such
fusion proteins activate/repress transcription, exhibit
altered DNA binding speci® city or participate in
novel protein± protein interactions. Thus, they are
thought to play a critical role in the neoplastic
transformation process.
The identi® cation of translocations associated
with a group of primitive sarcomas, and the sub-
sequent cloning of the chromosomal breakpoint re-
gions, has revealed that a common theme in these
tumors is the generation of chimeric transcription
factors. The fusion proteins are expressed exclu-
sively in the tumor cells, and function as potent
transcription factors where they are thought to con-
tribute to neoplastic transformation by mediating
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Table 1. Tumor-speci® c translocations associated with solid tumors
59 /39 fusion
Tumor Translocation product Type
Ewing’s sarcoma/ t(11;22)(q24;q12) EWS/FLI-1 RNA binding
PNET t(21;22)(q22;q12) EWS/ERG ETS TF
t(7;22)(p22;q12) EWS/ETV1
Alveolar t(2;13)(q35;q14) PAX3/FKHR PB and HD/FD
rhabdomyosarcoma t(1;13)(p36;q14) PAX7/FKHR
Melanoma of soft parts t(12;22)(q13;q12) EWS/ATF1 RNA binding/
(clear cell sarcoma) bZIP TF
DSRCT t(11;22)(p13;q12) EWS/WT1 RNA binding/
Zn ® nger TF
Synovial sarcoma t(X;18)(p11.2;q11.2) SYT/SSX1 SH2/KRAB box
SYT/SSX2
Liposarcoma t(12:16)(q13;p11) CHOP/FUS-TLS RNA binding/
(myxoid and round cell) bZip TF
aberrant expression of normal genes. Several of the
chimeric genes have been cloned and found to con-
fer a transformed phenotype when expressed in
vitro.
7± 11 The tumor-speci® c expression of the fusion
proteins make them likely candidates for tumor-
associated antigens (TAA), in which the junction
point creates a neo-antigenic determinant. The fo-
cus of this review will be on the translocation events
associated with Ewing’s sarcomas/primitive neu-
roectodermal tumors (PNETs) (ES), alveolar rhab-
domyosarcoma (ARMS), malignant melanoma of
soft parts (MMSP or clear cell sarcoma), desmo-
plastic small round cell tumor (DSRCT), synovial
sarcoma (SS), and liposarcoma (LS), and the poten-
tial for targeting the resulting chimeric proteins in
novel immunotherapies.
Tumor-associated chromosomal transloca-
tions in pediatric sarcomas
Ewing’s sarcoma/primitive neuroectodermal tumors
The ES/PNET family of tumors is a group of poorly
differentiated malignancies that include Ewing’s sar-
coma (ES), peripheral neuroepithelioma (PNET)
and Askin’s tumor. They are thought to originate
from the neuroectoderm, and show varying, but
limited degrees of neural differentiation. These tu-
mors express MIC2, a membrane protein that ap-
pears to function in cellular adhesion. The
expression of this antigen distinguishes these tumors
from other small round cell malignancies.
12,13 In
addition, approximately 85% of ES/PNET tumors
are characterized by t(11;22)(q24;q12).
14± 17 Delat-
tre et al. demonstrated that the t(11;22)(q24;q12)
rearranges the FLI1 gene (Friend leukemia inte-
gration site 1) on chromosome 11q24 with a hereto-
fore uncharacterized gene, EWS.
8,18 There is no
evidence for the expression of the reciprocal hybrid
transcript.
19
EWS encodes a 656-aa protein, the function of
which remains unclear. While this protein is ubiqui-
tously expressed, expression levels ¯ uctuate with the
cell cycle.
19± 23 EWS contains two major functional
domains. The ® rst is the N-terminal region (exons
1± 7) consisting of a series of degenerate repeats that
resemble the transactivation domains of several
transcription factors, such as SP-1
24 while the se-
cond region, the C-terminal region, includes a puta-
tive RNA-binding domain (exons 11± 13) de® ned by
a conserved 80-aa domain.
24 Wild-type EWS has
been shown to bind RNA in vitro and EWS/GAL4
fusion proteins can activate a reporter gene, suggest-
ing a role for EWS in transcription.
9,21,23
FLI1, a member of the ETS family of transcrip-
tion factors, is the human homologue of the murine
FLI1 gene and is normally expressed in hematopoi-
etic tissues.
25 The ETS DNA-binding domain, usu-
ally located in the C-terminal portion of the protein,
is an 85-aa region that recognizes target genes
through a conserved GGAA/T sequence.
26 In FLI1,
the ETS domain is encoded in the C-terminus, and
the N-terminal region contains a domain that is
functional in reporter gene assays.
9,27
EWS/FLI1 is a potent transcription factor that
can transform NIH 3T3 cells, and studies have
shown that sequences in both EWS and FLI1 are
essential for transformation.
7± 9 To better de® ne the
functional regions of the fusion protein, substitu-
tions were made in which domain 1 of EWS was
replaced with a strong heterologous activation do-
main. Many of these fusion proteins retained ac-
tivity, although not all were transforming.
7,23
Domain 2 of EWS could also be exchanged with a
weak transcriptional activation domain from TLS/
FUS without loss of activity. Thus, these data sup-
port a model wherein the EWS region of EWS/FLI1
confers strong transactivation through domain 1
with additional properties (protein± protein interac-
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Several variants of the t(11;22)(q24;q12) EWS/
FLI1 gene fusion have been described,
8,19 but most
include EWS exons 1± 7 and FLI 1 exons 8 and 9.
2,28
Therefore, the amino terminal portion of EWS is
always fused to the carboxy terminal region of
FLI1
8,19 which suggests that these EWS/FLI1 vari-
ants contribute to oncogenesis by similar mecha-
nisms.
EWS/FLI1 and FLI1 have similar DNA-binding
speci® city and af® nities,
9,29 but EWS/FLI1 is a more
potent transactivator than FLI1.
9,29,30 In vitro studies
suggested that EWS/FLI1 functioned as a transacti-
vator at 10-fold lower concentrations than FLI1.
29
Thus, it is likely that EWS/FLI1 mediates its trans-
forming effects, at least in part, by transactivation of
FLI1 targets or promoters containing ETS-binding
sites. Because c-MYC is upregulated in some tu-
mors, including ES, one potential target gene of
EWS/FLI1 was thought to be c-MYC. A study by
Bailly et al. investigated transactivation of c-MYC by
EWS/FLI1 using transient tranfection HeLa cells.
These experiments suggested that EWS/FLI1
played a role in increased expression of c-MYC.
However, direct binding of EWS/FLI1 to ETS-
binding sites in the c-MYC promoter could not be
detected using gel shift mobility assays. Thus, EWS/
FLI1 upregulates c-MYC, albeit by an indirect
mechanism yet to be elucidated.
29
Recent studies suggest that EWS/FLI and FLI1
exhibit some differences in DNA-binding and pro-
tein± protein interactions.
31 Therefore, it is possible
that EWS/FLI1 also contributes to transformation
by activating genes not normally regulated by FLI1.
Studies are ongoing to identify the normal targets of
EWS/FLI1 and FLI1. Braun et al.
32 utilized repre-
sentational difference analysis (RDA) to identify
differentially expressed genes from NIH 3T3 cells
containing EWS/FLI1 or normal FLI1. This ap-
proach revealed that several transcripts were depen-
dent on the fusion protein for expression, while at
least two transcripts were repressed. Stromelysin 1,
cytokeratin 15, and a murine homolog of cy-
tochrome P-450 F1 are all induced following ex-
pression of EWS/FLI1. However, the kinetics of
expression argue against the direct upregulation of
all of these target genes. The elucidation of such
primary targets will provide insight into the role of
EWS/FLI1 in transformation. It is likely that the
oncogenic properties of EWS/FLI1 results from
both the inappropriate expression of FLI1 target
genes, as well as novel protein± protein interactions
which may lead to the activation of non-FLI1 target
genes. Studies that utilized antisense EWS/FLI1
cDNA to diminish EWS/FLI1 RNA levels demon-
strated markedly decreased cell growth in vitro,
thereby implicating the fusion protein as a key con-
tributor to aberrant growth.
33,34 EWS/FLI1 may
contribute to oncogenesis is by inhibition or alter-
ation of normal apoptotic pathways. Yi et al.
35 ob-
served suppression of apoptosis in Ewing’s sarcoma
cells expressing EWS/FLI1 and found that ex-
pression of the fusion protein antisense RNA in-
creased susceptibility to apoptosis. Thus,
EWS/FLI1 may contribute to malignant transform-
ation by alteration of more than one gene or gene
pathways.
The EWS gene is also involved in several other
tumor-associated translocations. For example, a
minority of PNETs present with a variant t(21; 22)
translocation that fuses EWS to the ERG gene.
3,28,36
Like FLI1, ERG is a member of the ETS family of
transcription factors and may regulate similar target
genes.
32 Studies are underway to identify ERG
target genes. Several lines of evidence suggest EWS/
ERG may contribute to neoplastic transformation
by the same or similar mechanisms as EWS/FLI1.
First, PNETs containing EWS/FLI1 or EWS/ERG
are phenotypically and clinically indistinguish-
able.
2,36 As is seen in EWS/FLI1, EWS/ERG fusions
include EWS exons 1± 7, with ERG sequences en-
coding the ETS domain.
3,28,36 The fusion protein
also functions as a transcription factor and requires
the same regions for transactivation de® ned in EWS/
FLI1 studies.
21 Furthermore, cells expressing EWS/
ERG have a decreased ability to undergo apoptosis.
These cells could be made susceptible to apoptosis
by the expression of EWS/ERG antisense RNA.
35
Therefore, it is likely that EWS/ERG fusions con-
tribute to oncogenesis in a manner similar to EWS/
FLI1.
A rare, third variant, t(7:22)(p22;q12) has been
described
37 in which EWS is fused to ETVI, the
human homolog of the murine ETS gene ER81. It is
likely that EWS/ETV1 contributes to malignant
transformation by mediating aberrant transcription
and/or repressing expression of regulatory genes.
However, RDA analysis of EWS/ETV1 revealed
that only one of eight EWS/FLI1 target genes was
upregulated by EWS/ETV1. This suggests that
EWS/ETV1 activates only a portion of the EWS/
FLI1 transformation pathway, requiring other alter-
ations for tumorigenesis, or that EWS/ETV1 plays a
minor role in transformation. Further studies are
needed to de® ne the effect of EWS/ETV1 on nor-
mal gene expression.
Recently, Peter et al. identi® ed a new member of
the ETS family fused to EWS in Ewing’s sarcoma,
the FEV gene.
38 FEV, which maps to chromosome
2, encodes a 238-aa protein. Its expression is highly
restricted with protein being detected only in adult
prostate and small intestines, but not in other fetal
or adult tissues. FEV contains an ETS DNA bind-
ing domain closely related to that of ERG and
FLI1; however, in contrast to these proteins, FEV
has a small N-terminal region of only 42 aa which
suggests that it lacks important transcription regula-
tory domains present in other ETS family proteins.
It is unclear whether or not EWS/FEV alters tran-
scription of similar target genes than other EWS
fusion proteins. Further studies are needed to80 T. J. Goletz et al.
elucidate this fusion protein’s role in the pathogene-
sis of ES.
The common denominator of these tumors is that
all are primitive neuroectodermal sarcomas occur-
ring in children and young adults, and the evidence
strongly implicates EWS fusions as key mediators of
malignant transformation. There is also strong evi-
dence to suggest that these fusion proteins contrib-
ute to oncogenesis by aberrant expression of target
genes (activation and repression), as well as altering
the expression of genes not normally regulated by
the native transcription factors.
32 Furthermore,
these genes may effect normal growth regulation by
interfering with apoptotic pathways.
35
Alveolar rhabdomyosarcoma (ARMS)
Rhabdomyosarcoma is the most common soft tissue
sarcoma in pediatric patients, with approximately
250 cases per year in the United States. Roughly
20% of these cases are of the alveolar morphological
type (ARMS) which is characterized by alveolar-like
spaces formed by ® brovascular septa. These spaces
are ® lled with malignant cells that are distinguished
by their eosinophilic cytoplasm. Approximately 80%
of ARMS express a translocation involving the long
arms of chromosomes 2 and 13 t(2;13)(q35;q14),
which results in the juxtapositioning of a truncated
PAX3 gene of chromosome 2 to the 39 -terminal
region of the FKHR gene of chromosome 13.
39± 43
The PAX family of transcription factors play im-
portant roles during embryonic development, partic-
ularly in morphogenesis and pattern formation.
44
These genes contain a paired-box (PB) DNA-
binding domain and some also contain a homeobox
(HB) DNA-binding domain. Overexpression of
these genes can result in oncogenic transform-
ation
10,11 and loss of function mutations has been
observed in several genetic diseases, including
Waardenburg syndrome.
45
FKHR, formally known as ALV,
41 is a member of
the fork-head domain (FD) family of transcription
factors which contain a conserved DNA-binding
motif related to the Drosophila region-speci® c home-
otic gene fork-head. This family of transcription
factors normally functions during embryogenesis.
The FKHR gene is ubiquitously expressed and func-
tions as a transcription factor.
The hybrid gene which results from the
t(2;13)(q35;q14) translocation encodes a fusion
protein containing the amino terminal portion of the
PAX3 protein including the PB and HB domains
joined to the carboxyl region of the FKHR protein
that is truncated within the winged helix DNA-
binding region, but retains a putative transactivation
domain. Evidence suggests that the DNA-binding
speci® cty of PAX3/FKHR is contributed by PAX3,
most likely through the PB and HB domains, while
FKHR contributes the transactivation region. Al-
though the DNA-binding activity of PAX3/FKHR is
less than wild-type PAX3, the fusion protein is a
more potent transactivator.
46± 49 Overexpression of
murine PAX3 transforms NIH 3T3 cells
11 and the
PAX3/FKHR fusion protein transformed chicken
embryo ® broblasts.
10 One possible mechanism of
transformation is through a gain of function, not
only by increased transactivation potency, but also
through constitutive and increased expression.
49,50
Interestingly, a recent study which utilized antisense
technology to downregulate PAX3/FKHR in ARMS
tumor cells demonstrated reduced cell viability,
which led to the conclusion that PAX3/FKHR may
contribute to malignant transformation through
suppression of apoptotic processes which would
normally cause cell death.
51
Interestingly, 10± 20% of ARMS tumors contain a
variant translocation, t(1;13)(p36;q14), that results
in the in-frame fusion of 59 PAX7 to 39 FKHR.
PAX7 and PAX3 are highly homologous in the PB
and HB domains, suggesting that they might recog-
nize similar target genes.
40± 43,52 Furthermore, the
PAX3/FKHR and PAX7/FKHR chimeric proteins
share structural similarities in that they both contain
intact N-terminal PB and HB regions fused to the
acidic and proline-rich C-terminal region of
FKHR.
41,42,52 Therefore, it is likely that these
translocations create similar chimeric transcription
factors that contribute to transformation by altering
expression of a common group of target genes.
50± 52
Malignant melanoma of soft parts (MMSP) or clear cell
sarcoma (CCS)
Malignant melanoma of soft parts (MMSP), also
known as clear cell sarcoma (CCS), is a rare, but
aggressive soft tissue sarcoma of muscle tendons and
aponeuroses that occurs most frequently in young
adults between the ages of 15 and 35 years.
53 Over
95% of MMSP cases occur in the extremities, and
only rarely (less than 2%) occur in the head and
neck region. Although MMSP is a melanin-produc-
ing tumor, there is no evidence to suggest that these
tumors are directly related to malignant melanoma.
MMSP is thought to have neuroectodermal origins
54
and expresses neural antigens, as well as markers of
melanin production, such as HMB-45. A t(12;22)
(q13;q12) translocation event is present in more
than 70% of these tumors
55,56 and molecular analy-
sis of the breakpoint reveals an EWS/ATF1 fusion.
This chimeric protein joins the 59 RNA-binding
region of the EWS gene and the 39 region of the
ATF1 gene, a member of the CREB/transcription
factor family of leucine zipper transcription factors
that has a bZIP domain for DNA binding and
protein± protein interaction.
57 This family of tran-
scription factors mediates transcription through
ATF-binding sites. The expression of these genes is
induced by cAMP, and they are activated by phos-
phorylation by cAMP-dependent protein kinase A
(PKA).
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The t(12; 22) translocation fuses the N-terminal
portion of EWS to the C-terminal region of ATF1,
retaining the bZIP domain. However, the PKA reg-
ulatory phosphorylation site is lost.
58 Thus, it is
likely that EWS/ATF1 could exhibit the DNA-bind-
ing speci® city of ATF1, and dimerize with CREB,
but would not be cAMP-inducible. EWS/ATF1
does activate promoters with ATF1 binding sites,
although not all such promoters were activated,
60
and some promoters were found to be repressed by
EWS/ATF1. Therefore, EWS/ATF1 may contribute
to malignant transformation by several mechanisms.
First, EWS/ATF1 may constitutively activate ATF1
target genes that are normally induced by cAMP, or
it may repress genes that normally function in
growth control. Alternatively, EWS/ATF1 may acti-
vate novel genes, perhaps genes regulated by other
CREB/ATF family members.
In most MMSP tumors, two hybrid transcripts
are generated and expressed by the t(12;22)
(p13;q12) translocation. The expression pro® le of
the fusion gene on der(12) chromosome is compat-
ible with the ubiquitous expression of ATF. How-
ever, this out-of-frame fusion results in a product
consisting of the ® rst 65 N-terminal amino acids of
ATF1, which is unlikely to bind DNA or dimerize,
making its role in transformation unclear. It is un-
likely that expression of the der(12) transcript is
essential in transformation given reports that 30% of
MMSP lack expression.
56
Desmoplastic small round cell tumor (DSRCT)
Desmoplastic small round cell tumor (DSRCT) is
an aggressive small round cell tumor that occurs
predominantly in abdominal serosal surfaces and
has a predilection for young males.
61 The tumor is a
primitive small round cell with features of divergent
differentiation, co-expressing epithelial, neural and
myogenic markers. The origin of this tumor remains
unclear, but it is most likely derived from the
mesothelium. Almost 100% of these tumors contain
a t(11;22)(p13;q12) translocation that fuses the 59
region of the EWS gene to the 39 region of WT1, a
tumor suppressor gene involved in a subset of
Wilms’ tumors.
62± 66 WT1 binds DNA through a
series of zinc ® ngers and represses the transcription
of certain genes. These zinc ® ngers are essential for
transcriptional repression. The chimeric protein
contains the N-terminal region of EWS fused to the
WT1 DNA-binding domain. Given that both the
wild-type EWS gene and EWS fusion proteins are
known to participate in transcriptional complexes, it
is likely that EWS/WT1 functions as a transcription
factor, possibly through WT1 targets. Therefore,
unlike the loss of function mutation in Wilm’s tu-
mor, the loss of the zinc ® nger region of WT1 in
EWS/WT1 serves to convert WT1 from a repressor
of transcription to a dominant transcriptional activa-
tor oncogene.
67
Synovial sarcoma (SS)
Synovial sarcoma is an aggressive soft-tissue malig-
nancy which occurs primarily in the extremities near
major joints (e.g. ankle, knee) of adolescents and
young adults. Virtually all synovial sarcomas contain
a translocation of chromosomes X and 18
68 with
approximately 70% involving t(X;18)(p11.2;q11.2).
This translocation event generates a fusion protein
from the 59 region of the SYT gene and the 39
region of SSX1 or SSX2.
69± 71 There is no evidence
of a transcript being expressed by the reciprical
hybrid der (18).
71 The function of the SYT gene is
unknown, and sequence analysis reveals no classical
structural motifs associated with DNA-binding or
transcriptional regulation. However, the presence of
SH2 and SH3 domains suggests that SYT might
function through protein± protein interaction. The
recent isolation of the mouse homolog of SYT re-
vealed that SYT is expressed ubiquitously during
early embryogenesis,
69 but expression is restricted
later in development to cartilage tissue, speci® c neu-
ronal cells and some epithelial-derived tissues. SYT
was also detectable in primary spermatocytes.
Several studies suggested that SS contained two
distinct X chromosome breakpoint sites. However,
the identi® cation of two closely related genes at
Xp11.2 established the involvement of distinct cod-
ing regions. Despite being 2 Mb apart, SSX1 and
SSX2 share 80% homology.
70 Both encode a 188-aa
protein with an N-terminal Kruppel-associated box
(KRAB) that is thought to function as a transcrip-
tion repressor domain.
72,73 Although these proteins
lack zinc ® nger motifs, the presence of the KRAB
sequences suggest a role in transcription. However,
this domain is not present in the chimeric protein,
which suggests that SSX1 and SSX2 sequences
contribute to transformation through novel protein±
protein interactions or some other function. SSX3,
another KRAB protein, is not implicated in t(X;
18)-positive SS,
74 but has high homology to SSX1
and SSX2 (95 and 90%, respectively). The study of
this gene may provide insight into the function of
SSX1 and SSX2.
Liposarcomas (LPS)
Liposarcomas (LS) are soft tissue tumors that occur
primarily in the extremities and retroperitoneum.
These tumors are from primitive mesenchymal cells
and they resemble fetal adipose tissue. Several
characteristic cytogenetic aberrations have been
identi® ed for adipose tumors. The most common
LS are myxoid round cell liposarcomas, and greater
than 90% of myxoid liposarcomas contain the
t(12;16)(q13;p11) translocation in which CHOP
on the long arm of chromosome 12 is fused to
FUS/TLS.
22,75± 77 However, this translocation event
has not been detected in other adipose tumors and,
therefore, may provide interesting insight into the
transformation process of this subset of tumors.82 T. J. Goletz et al.
FUS/TLS is structurally similar to EWS (. 50%
amino acid identity)
75 and is expressed at high levels
in all tissues examined.
22 TLS binds RNA and
encodes a strong transcriptional activation domain
in the N-terminal region.
78 Therefore, like EWS,
FUS/TLS may function as a nuclear RNA-binding
protein.
CHOP, also called GADD153, is a member of
the CCATT/enhancer-binding protein (C/EBP)
family of leucine zipper transcription factors that
regulate adipocyte differentiation. CHOP is ex-
pressed at low levels in adipocytes; however, mRNA
levels increase during conditions of stress such as
DNA damage. Overexpression of CHOP in NIH
3T3 cells results in growth arrest at G1/S.
79 Thus,
CHOP is thought to function as a dominant nega-
tive growth regulator.
80
In the TLS/CHOP fusion protein, the N-terminal
portion of TLS is joined to the entire CHOP coding
region.
75,76 TLS/CHOP can transform NIH 3T3
cells and studies indicate that transformation re-
quires sequences from both TLS and CHOP.
78 The
requirement for the C-terminal leucine zipper do-
main of CHOP for transformation suggests a crucial
role for C/EBP protein dimerization. Although it is
unclear whether normal wild-type CHOP activation
requires DNA-binding, the potential DNA-binding
region, a basic region of the bZIP domain, is re-
quired for transformation. The role of TLS se-
quences in transformation may be more than that of
a strong transactivator, since substitution of this
region with other potent transactivating domains did
not mediate transformation. However, substitutions
with EWS sequences were transforming.
78 There-
fore, TLS/CHOP may contribute to transformation
by mechanisms similar to those previously discussed
in EWS fusion proteins.
Potential immunotherapeutic approaches for
the treatment of pediatric sarcomas
Although multi-modality therapy has improved sur-
vival rates for the pediatric sarcomas described in
this review, patients often relapse, at which time
responses to multi-agent chemotherapy are brief or
non-existent. Furthermore, patients who present
with metastatic disease at diagnosis do very poorly
in spite of aggressive multi-modality therapy. There-
fore, efforts are needed to develop novel treatments,
such as immunotherapies. Studies over the past
decade have provided evidence that treatments
based on the manipulation of the immune system
can mediate regression of established metastatic
cancer. More speci® cally, cell-mediated immunity
can play a critical role in tumor regression.
T lymphocytes are most often categorized as
CD8
1 cytotoxic lymphocytes (CTL) or CD4
1
helper lymphocytes (Th), and both types of T cells
are known to play a role in tumor regression. Our
understanding of antigen processing, presentation,
and recognition has increased considerably in the
last two decades and has been expertly reviewed
elsewhere.
81 Brie¯ y, T cells recognize antigens as
short peptides that are bound to the cell surface in
the context of major histocompatibility (MHC)
molecules.
81,82 In the case of CD8
1 CTL, the T cell
receptor (TCR) recognizes short peptides (8± 10
amino acids) bound to MHC class I molecules.
These peptides are derived from endogenously ex-
pressed proteins which undergo proteolytic process-
ing in the cytosol by large proteosome complexes.
Peptide fragments are then transported into the
lumen of the endoplasmic reticulum (ER) by spe-
cialized transporters of antigen processing (TAP).
Once inside the ER, peptides associate with an
appropriate MHC class I molecule that is associated
with beta-2-microglobulin (b 2 m), an invariant sub-
unit which is thought to enhance ef® cient MHC
folding, optimize MHC/peptide binding, and in-
crease stability of the MHC/peptide complex during
transport to and expression on the cell surface.
Following peptide/MHC binding, the peptide/
MHC/b 2 m complexes transverse the ER and Golgi
apparatus, and are displayed on the cell’s surface
where they are subject to surveillance by CTL. In
the case of CD4
1 Th cells, the TCR recognize
slightly larger peptides (10± 25 aa) in the context of
MHC class II molecules. These peptides are typi-
cally derived from material or organisms which have
undergone endo/phagocytosis by APC. Thus, in
general, CD8
1 CTL recognize intracellular (en-
dogenous) peptides while CD4
1 T cells recognize
external (exogenous) protein fragments.
CTL can distinguish self from non-self peptides
associated with MHC class I molecules, so that
expression of viral proteins or altered cellular
proteins will be re¯ ected in the peptide/MHC com-
plexes displayed on the cell surface. Although the
tumor-speci® c fusion proteins described in this re-
view function as nuclear transcription factors, they
are still subject to the proteolytic processing and
presentation pathways described. There is exper-
imental evidence that tumor-associated nuclear
proteins, such as mutant p53, can induce immune
responses.
83± 88.
The identi® cation of TAA and an increased
understanding of the requirements for the induction
of cell-mediated immune responses (Table 2) has
led to advances in immunotherapy.
89 While a num-
ber of TAA have been identi® ed for several tumor
types,
90± 93 it is unclear whether all TAA will be
effective tumor regression antigens. Ideally, one
would like to identify and target TAA which play a
key role in neoplastic transformation, so that they
cannot be lost without loss of malignancy. The
tumor-associated translocations identi® ed for a
number of pediatric sarcomas such as ES and AR
may very well be such antigens, since they generate
functional chimeric transcription factors known to
contribute to abberrant gene expression. MoreMolecular alterations in pediatric sarcomas 83
Table 2. Immunotherapeutic approaches using tumor-associated antigens
Active immunotherapy using immunodominant peptides:
alone
with adjuvants
linked to helper peptides
Administered:
in lipids/liposomes
pulsed onto antigen-presenting cells (APCs)
Substituted peptides
immunodominant peptides with amino acid substitutions to increase
binding to MHC
Proteins
alone
with adjuvants
DNA
`naked’ DNA encoding cancer antigens administered using gene gun
intramuscular injection
associated/linked to lipids
Recombinant viruses
recombinant viruses, such as vaccinia, fowlpox or adenovirus, encoding
cancer antigens, alone or in combination with genes encoding
cytokines costimulatory molecules or immunostimulatory factors
Recombinant bacteria
recombinant bacteria such as bacillus calmette± guerin (BCG),
Salmonella or Listeria engineered to express cancer antigens
alone or with genes encoding cytokines, costimulatory
molecules or other immunostimulatory factors
Active immunotherapy followed by cytokines
Interleukin 2 (IL-2), IL-6, IL-10, IL-15
Passive immunotherapy with anti-tumor lymphocytes generated in vitro
Generation of CTL using immunodominant peptide-pulsed APCs
Generation of Th by coincubation of APC with antigenic peptides
speci® cally, the breakpoint junctions are likely neo-
antigens. Further, it should be possible to avoid
autoimmune responses by focusing on minimal pep-
tides corresponding to the sequences which span the
breakpoint, since these would not be present in
normal cells. This hypothesis was tested in animal
models using synthetic peptides corresponding to
the breakpoint junctions in ES and ARMS as im-
munogens. In these studies, peptide-pulsed APC
administered intravenously, generated CD8
1 CTL
responses capable of lysing peptide-pulsed tumor
cells in vitro as well as tumor cells transfected to
express the full-length fusion protein. Furthermore,
these responses were able to reduce or irradicate
tumor in vivo. These data demonstrate that the
chimeric fusion products resulting from chromo-
somal translocations can serve as neoantigens.
Because the translocation events are tumor speci® c,
therapies targeting the resulting fusion proteins
would be highly speci® c and potentially less toxic.
Clinical trials are currently underway in patients
with ES and ARMS to evaluate the generation of
anti-tumor responses using a similar approach. In
addition, studies are ongoing to not only identify
additional TAA, but also to gain an understanding
as to which TAA may serve as tumor rejection
antigens. Since it is clear that the immune system
does not react against all possible antigenic determi-
nants, characterization of the immunodominant
peptides in the tumor regression antigens will fur-
ther aid in the development of effective treatments.
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The identi® cation of TAA and the cloning of the
genes which encode them provides numerous op-
portunities for the development of cancer therapies
(Table 2). Therapies could utilize the TAA protein
either alone or with adjuvants. Alternatively, the
administration of peptides derived from the TAA
protein administered alone, with adjuvants or in
combination with helper peptides, has certain ad-
vantages in that this approach has been demon-
strated to generate T cell responses while having
minimal risk in the induction of unwanted and
potentially dangerous autoimmune reactions. Anti-
tumor responses generated by peptide vaccination
may be augmented by manipulation of the route/
mode of administration. The cloning of genes en-
coding TAA will facilitate their expression in
high-ef® ciency expression systems, such as recombi-
nant viruses or bacteria. These vectors can be engi-
neered to express the TAA alone or in conjunction
with cytokine genes or genes encoding costimula-
tory molecules. Furthermore, direct injection into
muscle of DNA encoding antigens or the use of
`gene guns’ in which DNA is attached to small84 T. J. Goletz et al.
particles that are mechanically propelled into cells
is also an effective method of inducing immune
responses.
95± 100
Anti-tumor responses have been generated by in
vitro sensitization of peripheral blood lymphocytes
(PBL) to peptide-pulsed APC or irradiated tumor
cells. Repeated in vitro sensitization using im-
munodominant peptides from melanoma antigens
pulsed onto autologous peripheral blood mononu-
clear cells in the presence of IL-2 resulted in the
expansion of CTL (10,000-fold) over a 6-week pe-
riod. Cells generated by this approach showed im-
mune reactivity 50± 100 times greater than
corresponding tumor in® ltrating lymphocytes
(TIL)
101 and speci® cally recognized the appropriate
immunodominant peptide as well as tumor cells as
measured by lysis and cytokine release. Studies in
experimental animal models suggest that speci® c
tumor recognition as determined by lysis and cy-
tokine secretion assays correlated highly with in vivo
anti-tumor effects.
102 These correlates have also
been observed in patients treated with autologous
TIL.
103,104 In several other studies, T cells stimu-
lated in vitro were capable of recognizing and lysing
target cells pulsed with peptides known to bind to a
particular MHC class I molecule; however, these
same T cells were often incapable of recognizing
and lysing the low levels of processed peptides ex-
pressed by tumor cells.
105 Thus, there is consider-
able heterogeneity in anti-tumor responses.
Summary
The generation of chimeric transcription factors is a
common consequence of chromosomal transloca-
tions in solid tumors. The resulting fusion proteins
have been shown, in several cases, to have trans-
forming activity. Chimeric oncoproteins may func-
tion through several mechanisms. First, a strong
activation domain from one gene may be fused to
the DNA-binding speci® city region of another gene,
leading to dysregulated expression of target genes.
The fusion proteins associated with MMSP, ARMS,
and PNETs are examples of this mechanism. How-
ever, in myxoid liposarcoma, the FUS/CHOP gene
product appears to mediate its effect on transcrip-
tion through protein± protein interactions and may
not require DNA-binding. Second, a fusion partner
may contribute more than an activation domain.
For example, the EWS/FLI1 fusion protein of ES
seems to combine the transactivation domain of
EWS with the DNA-binding region of FLI1. How-
ever, the fusion protein appears to mediate novel
protein± protein/protein± nucleic acid interactions.
Also, the chimeric oncoprotein may heterodimerize
with other transcription factors. For example, the
heterodimerization of TLS/CHOP with C/EBP with
C/EBP family members regulates adipocyte growth
in a dominant-negative manner. Finally, chimeric
genes may be overexpressed as a result of a strong
promoter region from one of the partner genes.
However, this mechanism has not been observed in
solid tumors, but may be relevant in hematopoietic
malignancies. Nonetheless, it is likely that ex-
pression of hybrid proteins in solid tumors dysregu-
lates the transcription of key growth control genes or
pathways, thereby promoting tumorigenesis.
While fusion proteins are likely to invoke a combi-
nation of the aforementioned mechanisms, the re-
dundancy of their role in oncogenesis is noteworthy.
The multiple interchange of functional domains
from related genes such as FLI1 and ERG in
PNETs, PAX3 and PAX7 in ARMS and SSX1 and
SSX2 in SS result in similar tumor phenotypes.
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Domain-swap experiments involving EWS for TLS
in TLS/CHOP showed that substitutions can be
made with little change in morphology. However,
other experiments in which FLI1 was exchanged for
CHOP in fusions with TLS or EWS had an effect
on cell morphology, such that the morphology in
some cases was dependent on the DNA-binding
region of the chimeric transcription factor. Finally,
of note is the early onset of many of these tumors.
This suggests that the genes involved in sarcoma-as-
sociated translocations have speci® c patterns of de-
velopmental regulation, and that dysregulation of
this temporal regulation has profound effects.
Attempts at developing new therapeutic ap-
proaches to the treatment of these tumors have
included immunotherapy. However, successful im-
munotherapeutic stratagies must meet several cri-
teria, the ® rst of which is the expression of TAA that
are recognized by T lymphocytes. In the case of the
sarcomas presented in this review, the chimeric
transcription factors represent potential TAA. Stud-
ies in experimental animals suggest that the translo-
cation breakpoints in ES and ARMS represent
neoantigens which can be recognized by CTL. Fur-
thermore, these response were suf® cient to mediate
in vivo tumor regression in animal models. Clinical
vaccine studies are ongoing to evaluate the ability of
these TAA to serve as tumor regression antigens.
Finally, identi® cation of the immunodominant epi-
topes in tumor regression antigens will favor the
induction of effective anti-tumor responses. Screen-
ing vaccines and various delivery systems (peptides
or proteins in adjuvants or on dendritic cells, DNA,
viruses) in animals, such as HLA-transgenics, will
help to identify the most promising vaccines for use
in clinical trials.
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